Document is current
Any future updates will be listed below
-
Authors
Gambichler, T. https://orcid.org/0000-0001-7862-3695
Finis, C.
Abu Rached, N.
Scheel, C. H.
Becker, J. C.
Lang, K.
Käfferlein, H. U.
Brüning, T.
Abolmaali, N.
Susok, L.
-
Funding
Funding for this research was provided by:
Universitätsklinikum der Ruhr-Universität Bochum
- License Information
-
More Information
Article History
Received: 11 March 2022
Accepted: 29 March 2022
First Online: 13 April 2022
Declarations
:
: TG has received speakers and/or advisory board honoraria from BMS, Sanofi-Genzyme, MSD, Novartis Pharma, Roche, Abbvie, Almirall, Janssen, Lilly, Pfizer, Pierre Fabre, Merck-Serono, outside the submitted work. JCB is receiving speaker’s bureau honoraria from Amgen, Pfizer, Merck-Serono and Sanofi, is a paid consultant/advisory board member for eTheRNA, Merck-Serono, Pfizer, 4SC and Sanofi. His group receives research grants from Bristol-Myers Squibb, Merck Serono, and Alcedis. LS has received speakers and/or advisory board honoraria from BMS, Sun-Pharma, MSD, and Novartis. The other authors report no conflicts or competing interests.
: This non-interventional study was approved by Institutional Review Board at the Ruhr-University Bochum (IRB Study ID #16-5985). All procedures performed in studies involving human participants or their data were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
